SINTX Technologies Regains Compliance With NASDAQ Minimum Bid Price Listing Requirement
SINTX Technologies has announced its compliance with NASDAQ's minimum bid price requirements for continued listing. This follows a notice from NASDAQ indicating that SINTX's common stock closed at or above $1.00 for at least ten consecutive business days, from June 22 to July 8, 2020. The matter concerning Listing Rule 5550(a)(2) is now resolved. SINTX focuses on manufacturing and developing silicon nitride ceramics for various applications, bolstered by its FDA-registered and ISO 13485 certified facility.
- Regained compliance with NASDAQ's minimum bid price requirements.
- Closing bid price maintained at $1.00 or greater for 10 consecutive days.
- SINTX operates in an FDA-registered and ISO 13485 certified facility.
- None.
SALT LAKE CITY, UT, July 14, 2020 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an original equipment manufacturer (OEM) ceramics company focused on silicon nitride and its applications is pleased to announce that it has received a letter from the NASDAQ Listing Qualifications Staff notifying the Company that it has regained compliance with NASDAQ's minimum bid price requirements for continued listing on the Nasdaq Capital Market. The letter noted that as a result of the closing bid price of the Company's common stock having been at
About SINTX Technologies, Inc.
SINTX Technologies is an OEM ceramics company that develops and commercializes silicon nitride for medical and non-medical applications. The core strength of SINTX Technologies is the manufacturing, research, and development of silicon nitride ceramics for external partners. The Company manufactures silicon nitride material and components in its FDA registered and ISO 13485 certified facility.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA) that are subject to a number of risks and uncertainties. Risks and uncertainties that may cause such differences include, among other things, that future studies may not confirm the antiviral properties of silicon nitride; that application of silicon nitride to products may not result in products with antiviral properties; uncertainties inherent in research and development, including the cost and time required advance our products to regulatory submission; market acceptance of our products once cleared and commercialized; our ability to raise additional funding and other competitive developments. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations and beliefs. There can be no assurance that any of the anticipated results will occur on a timely basis or at all due to certain risks and uncertainties, a discussion of which can be found in SINTX’s Risk Factors disclosure in its Annual Report on Form 10-K, filed with the Securities and Exchange Commission (SEC) on March 26, 2020, and in SINTX’s other filings with the SEC. SINTX disclaims any obligation to update any forward-looking statements. SINTX undertakes no obligation to publicly revise or update the forward-looking statements to reflect events or circumstances that arise after the date of this report.
Contact:
SINTX Technologies
801.839.3502
IR@sintx.com
FAQ
What is the recent NASDAQ compliance news for SINT?
When was SINTX's compliance confirmed?
What impact does NASDAQ compliance have on SINT stock?
What does SINTX Technologies specialize in?
